Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Dermatol. Feb 2, 2015; 4(1): 50-56
Published online Feb 2, 2015. doi: 10.5314/wjd.v4.i1.50
Primary cutaneous B cell lymphoma: Clinical features, diagnosis and treatment
Fergun Yilmaz, Nur Soyer, Filiz Vural
Fergun Yilmaz, Nur Soyer, Filiz Vural, Department of Hematology, Ege University, 35100 Izmir, Turkey
Author contributions: Yilmaz F, Soyer N and Vural F contributed to this paper.
Conflict-of-interest: The authors declare no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Filiz Vural, MD, Department of Hematology, Ege University Hospital, Bornova, 35100 Izmir, Turkey.
Telephone: +90-23-23904541
Received: October 2, 2014
Peer-review started: October 3, 2014
First decision: November 27, 2014
Revised: December 18, 2014
Accepted: January 9, 2015
Article in press: Janurary 12, 2015
Published online: February 2, 2015

Primary cutaneous B cell lymphoma (PCBCL) is defined as B cell lymphomas that presents in the skin without any evidence of extra-cutaneous involvement at diagnosis. They are the second most common type of primary cutaneous lymphomas accounting for 25%-30%. Since the prognosis and treatment differ from systemic lymphomas involving the skin, differential diagnosis is very important. PCBCL is a heterogeneous group of disease comprising different B cell lymphomas with distinct treatment and prognosis. PCBCL is divided into 5 subclasses according to World Health Organization and European Organization of Research and Treatment of Cancer classification. Primary cutaneous marginal zone lymphoma and primary cutaneous follicle center lymphoma are indolent forms and often confined to skin at presentation and during the course of the disease. But primary cutaneous diffuse large B cell lymphoma, leg type and intravascular large B cell lymphoma are more aggressive forms that may disseminate to extra-cutaneous tissues. There is not a treatment consensus since they are rare entities. Local therapies like radiotherapy, surgery or intralesional steroids are options for localized disease in indolent forms. More disseminated disease may be treated with a systemic therapy like single agent rituximab. However combination chemotherapies which are used in systemic lymphomas are also required for aggressive PCBCL. Although indolent forms have relatively better prognosis, early relapses and disseminated diseases are mostly observed in aggressive form with a consequent poor prognosis.

Keywords: Primary cutaneous lymphomas, Diagnosis, Treatment, Bcell lymphoma

Core tip: Primary cutaneous B cell lymphoma is a type of lymphoma that presents in the skin without evidence of extra-cutaneous involvement. Prognosis and treatment being different from systemic lymphomas involving the skin makes differential diagnosis very important. It is a heterogeneous group of diseases that consists of indolent (primary cutaneous marginal zone lymphoma, primary cutaneous follicle centre lymphoma) and aggressive forms (primary cutaneous diffuse large B cell lymphoma, leg type and intravascular large B cell lymphoma). The indolent forms are mostly confined to the skin and have good prognosis whereas aggressive forms present with disseminated disease and are treated mostly with systemic combination chemotherapies.